Please try another search
Coegin Pharma AB, a biotechnology company, engages in the discovery and development of dermacosmetic products and drugs for the treatment of serious diseases associated with diabetes and cancer. Its products include AVX001 GEL drug candidate, which is in phase 2 clinical study for the treatment of actinic keratosis and in phase 1 clinical study for the treatment of basal cell carcinoma; AVX420 drug candidate in preclinical study for the indication of leukemia; FOL026, a peptide-based drug in preclinical study for the prevention of cardiovascular complications in diabetes; AVX420/FOL026 therapy in preclinical study for the treatment of kidney and liver fibrosis; and FOL005 for the treatment of stimulation of hair growth. The company was founded in 2005 and is based in Lund, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Odd Hjelmeland | - | - | Director |
Jan Erik Foss | - | - | Director |
Mikael Ørum | - | - | Chief Executive Officer and President |
Farzad Abdi-Dezfuli | - | - | Director |
J. A. Jongejan | - | - | Member of Scientific Advisory Board |
Edward A. Dennis | 81 | - | Member of Scientific Advisory Board |
Erlend Skagseth | 68 | 2020 | Director |
Joseph V. Bonventre | 73 | - | Member of Scientific Advisory Board |
Jorgen Serup | - | - | Member of Scientific Advisory Board |
George Kokotos | - | - | Member of Scientific Advisory Board |
Thoas Fioretos | 61 | 2022 | Director |
Eva Sjokvist Saers | 61 | 2023 | Chairman of the Board |
Jens Eriksson | 49 | 2023 | CEO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review